[LETTERS TO THE EDITOR]

**Anti-mitochondrial M2 Antibodies and Myopathy:
Author's Reply**

Key words: anti-mitochondrial antibody, atrial fibrillation, cardiomyopathy, primary biliary cholangitis, supraventricular arrhythmia

(Intern Med 57: 1189, 2018)

(DOI: 10.2169/internalmedicine.0107-17)

The Authors Reply We would like to thank Drs. Finsterer and Zarrouk-Mahjoub (1) for their interest in our recent publication in *Internal Medicine* regarding the enhanced risk of supraventricular arrhythmia in patients who are positive for anti-mitochondrial M2 (AMA-M2) antibodies (2). A key statement in their letter reads, "Overall, this interesting study could be more meaningful if a prospective design would have been applied, if more clinical data would have been collected, and if patients would have been more extensively investigated for cardiac disease".

Their suggestions regarding the methods of diagnosing myopathy, evaluating the prognosis, confirming atrial involvement, investigating the frequency of concomitant autonomic neuropathy, and detecting supraventricular and ventricular arrhythmias, as well as the associated medications, are quite important. The following statement is also important, "The longer an electrocardiogram is recorded, the higher the probability that arrhythmias are detected". This statement is important for any observational studies focusing on the frequency of cardiac arrhythmias. As Drs. Finsterer and Zarrouk-Mahjoub correctly pointed out, the present study is associated with several potential limitations because this observational study was retrospective in nature and because it was conducted in a single center. As we have already fully described in the main text (2), we do recognize these limitations. Unfortunately, these limitations make it difficult to supply complete answers to all of their queries within the context of the present study cohort. As they implied in their letter, it would not be meaningful to provide additional data from limited sources.

In spite of these potential limitations, however, we would

like to stress our key observational finding, that supraventricular arrhythmias were identified in one seventh of the patients with positive AMA-M2 test results. The possible association between AMA-M2 and atrial myocardial involvement that was suggested in the present study should be verified in the future, using a prospective and multi-center study design, as they suggested in their final key statement. Although we have discussed a possible mechanism of AMA-M2-associated myocardial involvement and supraventricular arrhythmias, it does not go beyond speculation at the present time. Based on their interest and kind response to our investigation (1), we hope that the present study will arouse the interest of many physicians, leading them to maintain continuous observation and to accumulate cases of AMA-M2-positive patients in routine clinical practice. This helps to clarify the mechanism of myocardial involvement and supraventricular arrhythmias.

Author's disclosure of potential Conflicts of Interest (COI).

Koji Fukuzawa: Research funding, Medtronic Japan and St. Jude Medical Japan. Kunihiro Kiuchi: Research funding, Medtronic Japan and St. Jude Medical Japan. Ken-ichi Hirata: Research funding, Medtronic Japan and St. Jude Medical Japan.

Hiroki Konishi¹, Koji Fukuzawa^{1,2}, Shumpei Mori¹, Seimi Satomi-Kobayashi¹, Kunihiro Kiuchi^{1,2}, Atsushi Suzuki¹, Tomomi Akita¹, Yoshihiko Yano³, Akihiro Yoshida¹ and Ken-ichi Hirata^{1,2}

References

1. Finsterer J, Zarrouk-Mahjoub S. Letters to the Editor. Anti-mitochondrial M2 antibodies and myopathy. Intern Med 2017 [Submitted].
2. Konishi H, Fukuzawa K, Mori S, et al. Anti-mitochondrial M2 antibodies enhance the risk of supraventricular arrhythmias in patients with elevated hepatobiliary enzyme levels. Intern Med 56: 1771-1779, 2017.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

¹Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan, ²Section of Arrhythmia, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan and ³Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan

Received: August 21, 2017; Accepted: August 22, 2017; Advance Publication by J-STAGE: December 27, 2017

Correspondence to Dr. Koji Fukuzawa, kfuku@med.kobe-u.ac.jp

© 2018 The Japanese Society of Internal Medicine. Intern Med 57: 1189, 2018